Multiple Myeloma

HIRB #2019-32/ Janssen #MM3019 (CEPHIUS): A Phase 3 Study Comparing Daratumumab, Velcade (Bortezomib), Lenalidomide, and Dexamethasone (DVRd) vs Velcade, Lenalidomide, and Dexamethasone (VRd) in Subjects with Previously Untreated Multiple Myeloma who are not Intended for Initial Stem Cell Transplant